Skip to main content
B

BrightPath Biotherapeutics Co., Ltd. — Investor Relations & Filings

Ticker · 4594 ISIN · JP3274140007 T Manufacturing
Open in API
Filings indexed 69 across all filing types
Latest filing 2022-12-19 Annual Report
Country JP Japan
Listing T 4594

About BrightPath Biotherapeutics Co., Ltd.

https://www.brightpathbio.com/english/

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Recent filings

Filing Released Lang Actions
訂正有価証券報告書－第16期(平成30年4月1日－平成31年3月31日)
Annual Report Classification · 1% confidence The document is a 'Correction Report' (訂正報告書) for a previously filed 'Annual Securities Report' (有価証券報告書) under the Financial Instruments and Exchange Act of Japan. It contains detailed financial tables, historical data, and business descriptions for BrightPath Biotherapeutics Co., Ltd. While it is a correction, it functions as a comprehensive financial disclosure document containing substantive financial data and analysis, fitting the criteria for an Annual Report (10-K) equivalent in the Japanese regulatory context. FY 2018
2022-12-19 Japanese
訂正有価証券報告書－第17期(平成31年4月1日－令和2年3月31日)
Annual Report Classification · 1% confidence The document is a 'Correction Report' (訂正報告書) for an 'Annual Securities Report' (有価証券報告書) filed with the Kanto Local Finance Bureau. It contains detailed financial tables, business history, and corporate information for BrightPath Biotherapeutics Co., Ltd. for the 17th fiscal year. While it is a correction, it functions as a comprehensive financial disclosure document (10-K equivalent in the Japanese market). FY 2020
2022-12-19 Japanese
訂正有価証券報告書－第18期(令和2年4月1日－令和3年3月31日)
Audit Report / Information Classification · 1% confidence The document is a 'Correction Report' (訂正報告書) for an Annual Securities Report (有価証券報告書), as indicated by the header '有価証券報告書の訂正報告書'. It includes detailed financial tables, business history, and operational data for BrightPath Biotherapeutics Co., Ltd. While it is a correction to a 10-K equivalent (Annual Securities Report), in the context of the provided filing categories, it is a formal regulatory filing that updates previously submitted financial information. Since it is not the primary Annual Report itself but a formal regulatory amendment, it falls under the 'Regulatory Filings' (RNS) category as the most appropriate fallback for this type of official disclosure. FY 2021
2022-12-19 Japanese
訂正有価証券報告書－第19期(令和3年4月1日－令和4年3月31日)
Annual Report Classification · 1% confidence The document is a 'Correction Report' (訂正報告書) for an Annual Securities Report (有価証券報告書) filed with the Kanto Local Finance Bureau in Japan. It includes detailed financial data, management indicators, and business history for BrightPath Biotherapeutics. While it is a correction to a previously filed report, it contains substantive financial information and is a formal regulatory filing. Given the structure and content, it aligns with the 'Annual Report' (10-K) category as it serves as the official yearly financial disclosure document. FY 2022
2022-12-19 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, Article 24-4-8, Paragraph 1. This is a standard Japanese regulatory filing that accompanies a Quarterly Report (Shihanki Hokokusho) to confirm the accuracy of the report's contents. Since it is a regulatory filing required by law that does not fit into the specific categories of financial reports, presentations, or announcements, it falls under the general regulatory filings category.
2022-11-11 Japanese
四半期報告書－第20期第2四半期(令和4年7月1日－令和4年9月30日)
Interim / Quarterly Report Classification · 1% confidence The document is a '四半期報告書' (Quarterly Report) filed with the Kanto Local Finance Bureau in Japan, pursuant to the Financial Instruments and Exchange Act. It contains detailed financial statements, including the balance sheet, for the second quarter of the 20th fiscal period (April 1, 2022, to September 30, 2022). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report (IR). H1 2023
2022-11-11 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.